These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 28958787)

  • 1. Evaluation of the combined effects of pegylation and glycosylation on the stability of erythropoietin using a stability-indicating SE-HPLC.
    Abed HS; Al-Ghobashy MA; Fathalla FA; Salem MY
    Biologicals; 2017 Nov; 50():129-136. PubMed ID: 28958787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between Dynamic Light Scattering and Size Exclusion High Performance Liquid Chromatography for Monitoring the Effect of pH on Stability of Biopharmaceuticals.
    Al-Ghobashy MA; Mostafa MM; Abed HS; Fathalla FA; Salem MY
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Aug; 1060():1-9. PubMed ID: 28578190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Assessment of the Effect of Hyper-glycosylation on the Pattern and Kinetics of Degradation of Darbepoetin Alfa using a Stability-Indicating Orthogonal Testing Protocol.
    Moenes EM; Al-Ghobashy MA; Mohamed AA; Salem MY
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1072():405-414. PubMed ID: 29157782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, modeling, expression, and chemoselective PEGylation of a new nanosize cysteine analog of erythropoietin.
    Cohan RA; Madadkar-Sobhani A; Khanahmad H; Roohvand F; Aghasadeghi MR; Hedayati MH; Barghi Z; Ardestani MS; Inanlou DN; Norouzian D
    Int J Nanomedicine; 2011; 6():1217-27. PubMed ID: 21753873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of sialic acids on the pharmacokinetics of a PEGylated erythropoietin.
    Liu L; Li H; Hamilton SR; Gomathinayagam S; Rayfield WJ; van Maanen M; Yin KC; Hong L; Prueksaritanont T
    J Pharm Sci; 2012 Dec; 101(12):4414-8. PubMed ID: 22987365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stabilization of bacterially expressed erythropoietin by single site-specific introduction of short branched PEG chains at naturally occurring glycosylation sites.
    Hoffmann E; Streichert K; Nischan N; Seitz C; Brunner T; Schwagerus S; Hackenberger CP; Rubini M
    Mol Biosyst; 2016 May; 12(6):1750-5. PubMed ID: 26776361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PEGylation markedly enhances the in vivo potency of recombinant human non-glycosylated erythropoietin: a comparison with glycosylated erythropoietin.
    Wang YJ; Hao SJ; Liu YD; Hu T; Zhang GF; Zhang X; Qi QS; Ma GH; Su ZG
    J Control Release; 2010 Aug; 145(3):306-13. PubMed ID: 20427020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient preparation and PEGylation of recombinant human non-glycosylated erythropoietin expressed as inclusion body in E. coli.
    Wang YJ; Liu YD; Chen J; Hao SJ; Hu T; Ma GH; Su ZG
    Int J Pharm; 2010 Feb; 386(1-2):156-64. PubMed ID: 19932158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational and nonglycosylated systems: a simpler approach for development of nanosized PEGylated proteins.
    Mirzaei H; Kazemi B; Bandehpour M; Shoari A; Asgary V; Ardestani MS; Madadkar-Sobhani A; Cohan RA
    Drug Des Devel Ther; 2016; 10():1193-200. PubMed ID: 27042012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving the recombinant human erythropoietin glycosylation using microsome supplementation in CHO cell-free system.
    Gurramkonda C; Rao A; Borhani S; Pilli M; Deldari S; Ge X; Pezeshk N; Han TC; Tolosa M; Kostov Y; Tolosa L; Wood DW; Vattem K; Frey DD; Rao G
    Biotechnol Bioeng; 2018 May; 115(5):1253-1264. PubMed ID: 29384203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, modeling, and expression of erythropoietin cysteine analogs in Pichia pastoris: improvement of mean residence times and in vivo activities through cysteine-specific PEGylation.
    Maleki A; Madadkar-Sobhani A; Roohvand F; Najafabadi AR; Shafiee A; Khanahmad H; Cohan RA; Namvar N; Tajerzadeh H
    Eur J Pharm Biopharm; 2012 Apr; 80(3):499-507. PubMed ID: 22068050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of homogeneous, monopegylated erythropoietin analogs with preserved in vitro bioactivity.
    Long DL; Doherty DH; Eisenberg SP; Smith DJ; Rosendahl MS; Christensen KR; Edwards DP; Chlipala EA; Cox GN
    Exp Hematol; 2006 Jun; 34(6):697-704. PubMed ID: 16728273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of culture temperature on erythropoietin production and glycosylation in a perfusion culture of recombinant CHO cells.
    Ahn WS; Jeon JJ; Jeong YR; Lee SJ; Yoon SK
    Biotechnol Bioeng; 2008 Dec; 101(6):1234-44. PubMed ID: 18980186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A validated stability-indicating HPLC method for the determination of PEGylated puerarin in aqueous solutions.
    Liu X; Yu B; Wang N; Zhang B; Du F; He C; Ye Z
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Aug; 878(23):2061-6. PubMed ID: 20580327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin.
    Skibeli V; Nissen-Lie G; Torjesen P
    Blood; 2001 Dec; 98(13):3626-34. PubMed ID: 11739166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of in vivo efficacy of recombinant human erythropoietin by encapsulation in PEG-PLA micelle.
    Shi Y; Huang W; Liang R; Sun K; Zhang F; Liu W; Li Y
    Int J Nanomedicine; 2013; 8():1-11. PubMed ID: 23293515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semi-mechanistic Pharmacokinetic/Pharmacodynamic model of three pegylated rHuEPO and ior®EPOCIM in New Zealand rabbits.
    Reynaldo-Fernández G; Solozábal J; Amaro D; Fernández-Sánchez EM; Rodríguez-Vera L; Bermejo M; Mangas-Sanjuan V; Troconiz IF
    Eur J Pharm Sci; 2018 Jul; 120():123-132. PubMed ID: 29729414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of bioactivity and pharmacokinetic characteristics of PEGylated P.pastoris-expressed erythropoietin.
    Maleki A; Najafabadi AR; Roohvand F; Shafiee A; Khanahmad H; Faghihi H; Hedayati MH; Tajerzadeh H
    Drug Deliv; 2011 Nov; 18(8):570-7. PubMed ID: 21892875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PEGylation enhancement of pH stability of uricase via inhibitive tetramer dissociation.
    Tian H; Guo Y; Gao X; Yao W
    J Pharm Pharmacol; 2013 Jan; 65(1):53-63. PubMed ID: 23215688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Identification of a Non-Glycosylated Variant at Ser126 for O-Glycosylation Site from EPO BRP, Human Recombinant Erythropoietin by LC/MS Analysis.
    Byeon J; Lim YR; Kim HH; Suh JK
    Mol Cells; 2015 Jun; 38(6):496-505. PubMed ID: 26013384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.